Prescription drug · NDA
Strattera (atomoxetine hydrochloride) NDC 0002-3250
Atomoxetine hydrochloride 80 mg/1 · Capsule · Oral · Eli Lilly and Company
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 0002-3250-30 | 00002325030 | 30 CAPSULE in 1 BOTTLE (0002-3250-30)Marketed from Aug 24, 2005 |
How the 11-digit form is made: The labeler segment has 4 digits, so one leading zero is added to it (4-4-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Strattera
- Generic name (nonproprietary)
- atomoxetine hydrochloride
- Active ingredients
- Atomoxetine hydrochloride — 80 mg/1
- Dosage form
- Capsule
- Route
- Oral
- Labeler
- Eli Lilly and Company
- Product type
- Prescription drug
- Marketing category
- NDA — New Drug ApplicationApplication NDA 021411
- Marketing start
- Marketing end
- Other FDA classes
- Norepinephrine Uptake Inhibitors (Mechanism)
- Identifiers
- Product ID 0002-3250_91872928-d392-4750-ae69-dc977bc6e190SPL ID 91872928-d392-4750-ae69-dc977bc6e190SPL set ID 309de576-c318-404a-bc15-660c2b1876fbRxCUI 349591, 349592, 349593, 349594, 349595, 352317, 352318, 352319, 352320, 352321, 608139, 608143, 617945, 617947UNII 57WVB6I2W0UPC 0300023229304, 0300023228307, 0300023239303, 0300023251305, 0300023250308, 0300023227300, 0300023238306
- Pharmacologic class
- Norepinephrine Reuptake Inhibitor
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N400002325030followed by a unit qualifier and the quantityPackage 00002-3250-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective . This label includes a boxed warning.
Indications (excerpt from the label)
STRATTERA is indicated for the treatment of attention-deficit/hyperactivity disorder (ADHD) in adults and pediatric patients 6 years of age and older. STRATTERA is indicated as an integral part of a total treatment program for ADHD that may include other measures (psychological, educational, social) for patients with ADHD. STRATTERA ® is a selective norepinephrine reuptake inhibitor (SNRI) indicated for the treatment of ADHD in adults and pediatric patients 6 years of age and older. ( 1 )
Excerpt only. Read the full label for complete information.
Other NDCs under NDA 021411
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Stratteraatomoxetine hydrochloride | Atomoxetine hydrochloride 25 mg/1 | CapsuleOral | Eli Lilly and Company | 0002-3228 |
| Stratteraatomoxetine hydrochloride | Atomoxetine hydrochloride 18 mg/1 | CapsuleOral | Eli Lilly and Company | 0002-3238 |
| Stratteraatomoxetine hydrochloride | Atomoxetine hydrochloride 40 mg/1 | CapsuleOral | Eli Lilly and Company | 0002-3229 |
| Stratteraatomoxetine hydrochloride | Atomoxetine hydrochloride 60 mg/1 | CapsuleOral | Eli Lilly and Company | 0002-3239 |
| Stratteraatomoxetine hydrochloride | Atomoxetine hydrochloride 100 mg/1 | CapsuleOral | Eli Lilly and Company | 0002-3251 |
| Stratteraatomoxetine hydrochloride | Atomoxetine hydrochloride 10 mg/1 | CapsuleOral | Eli Lilly and Company | 0002-3227 |